Mode of progression in smoldering multiple myeloma: a study of 406 patients.

"Competing interests SVR reports grants from NIH, outside the submitted work. PK received research funding from Takeda Pharmaceuticals, Celgene, and Amgen. AD received research funding from Celgene, Millennium Pharmaceuticals, Pfizer, and Janssen and received a travel grant from Pfizer. MAG served as a consultant for Millennium Pharmaceuticals and received honoraria from Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Novartis, GlaxoSmithKline, Prothena, Ionis Pharmaceuticals, and Amgen. MQL received research funding from Celgene. SKK served as a consultant for Celgene, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Janssen, and Bristol-Myers Squibb and received research funding from Celgene, Millennium Pharmaceuticals, Novartis, Onyx Pharmaceuticals, AbbVie, Janssen, and Bristol-Myers Squibb. The remaining authors declare no competing interests."

"Supported in part by grants CA 168762 and CA186781 from the National Cancer Institute, Rockville, MD, USA, and the Marvin Family Grant."